Drug Trial Radar · NCT00199381
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
Last checked: Nov 20, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
504
Actual
Start
Oct 2005
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin Co., Ltd.
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
Conditions
- Parkinson's Disease
Interventions
IstradefyllineDrug
Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as Measured by Adverse EventsTime frame: Every 2 months up to 32 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyowa Pharmaceutical Inc.
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.